Enliven Therapeutics, Inc. (ELVN) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Enliven Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 50.84 at 11:15 am ET, low 49.42 at 3:45 pm ET.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
the bull case· 4
3
of the funds on file reporting a position in ELVN
n-portas of Jun 30 '2632
managers whose positions together make up four fifths of the reported value
13fJun 30 '26+25.71%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '266
disclosed supplier and customer ties in SEC filings
sec filingsedgarthe bear case· 2
8 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized4 of 21
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Enliven Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
213 managers report a position worth $4.1B between them, and 32 of them hold 80% of it.
ELVN (Enliven Therapeutics, Inc.) has 6 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.